Cellbox Solutions Secures €3.5 Million Funding to Enhance Worldwide Cell Transportation Technology

Cellbox Solutions, a leading warm-chain logistics technology company based in Cologne, has successfully secured €3.5 million in Series A financing, with the funding round still open for additional tranches until May 2026. The financing was led by the digital business angel network Companisto, along with existing investors such as NRW.BANK. The newly raised capital will be utilized to expand international production and sales operations, as well as to explore new application areas, particularly in the fields of cell and gene therapy and in vitro fertilization (IVF).

The Founder and CEO of Cellbox, Prof Dr Kathrin Adlkofer, expressed the company’s vision to revolutionize the global transportation of living cells. With the ongoing support from investors and the addition of experienced executives to the leadership team, Cellbox aims to lay the groundwork for sustainable international growth and broaden the reach of warm-chain logistics in clinical and research settings. The company believes that reliable live-cell transport will play a crucial role in the global life sciences value chain.

Recent coverage by EU-Startups indicates a growing trend of investment in European companies specializing in cell-based therapies, advanced biomanufacturing, and life sciences technologies. For instance, UK startup Tozaro secured €6.9 million to enhance partnerships and further develop its Smart Polymer platform for cost-effective cell and gene therapy production. In the Netherlands, QT Sense raised €4 million to advance a quantum sensing platform for real-time monitoring of cellular stress in biomedical and drug development research.

Similarly, Cellcolabs in Sweden secured €10.3 million to expand manufacturing capacity for stem cell therapies, while StemSight in Finland raised €2.3 million to progress stem-cell-based treatments for severe blindness. In France, biotech company baCta secured €7 million to scale its platform using programmable microorganisms for industrial and life sciences applications.

Collectively, these funding rounds represent over €33 million in disclosed investments in adjacent life sciences and biotechnology sectors during 2025-2026. Within this landscape, Cellbox Solutions occupies a critical segment of the value chain by focusing on the essential logistics infrastructure for transporting living cells under controlled physiological conditions. This area is anticipated to become increasingly vital as cell and gene therapies move towards broader clinical and commercial deployment.

Dr Robin Ghosh, Investment Manager at Companisto, highlighted Cellbox’s role in addressing a crucial gap in the life sciences value chain by ensuring the reliable transport of living cells under physiological conditions. As advanced therapies expand globally, logistics is identified as a key factor for success. Cellbox is viewed not merely as a product innovation but as a scalable platform with the potential to redefine the transportation of sensitive biological materials in research and clinical environments.

Established in 2017, Cellbox Solutions specializes in warm-chain logistics technology, offering innovative solutions for the global healthcare and life sciences industries to transport delicate biological materials and therapeutics that require controlled physiological conditions and cannot be frozen. The company’s portable CO₂ incubator platform, Cellbox, provides a regulated environment for the transportation of living cells, organs, tissues, and advanced biological materials. The platform allows for individual adjustment of temperature and CO₂ levels to ensure consistent incubation conditions during shipment.

Cellbox’s warm-chain technology enables continuous control of shipment conditions for up to 48 hours, preserving the viability and functionality of cells during transport. The appointment of Dr Bernd Muehlenweg as CBO and CFO of Cellbox marks a significant step in the company’s growth phase. Dr Muehlenweg emphasized Cellbox’s contribution to setting a new standard in the transportation of living cells by ensuring safe, controlled, and reproducible transport under physiological conditions.

The investment round signifies a milestone in expanding Cellbox’s global presence and establishing the company as a standard for living cell shipment and warm-chain logistics worldwide. The patented platform and strong regulatory positioning provide a solid foundation for global expansion across various life sciences applications, including the rapidly growing field of cell and gene therapies. Dr Muehlenweg looks forward to enhancing commercial operations, expanding service offerings, and building organizational structures to support international growth.

In the long run, Cellbox aims to position warm-chain logistics as the preferred global approach for transporting living cells, cell therapies, and sensitive biological materials, further enhancing reliability and reproducibility in the life sciences sector. With a focus on innovation and excellence, Cellbox Solutions continues to lead the way in revolutionizing the transportation of living cells for various applications in healthcare and life sciences.